Core Viewpoint - China Evergrande's stock has been delisted, marking the end of its 16-year listing journey, while the real estate sector experiences a temporary rally due to favorable market policies [1][3]. Group 1: Stock Performance and Market Reaction - On August 25, 2023, major real estate stocks in both A-shares and H-shares saw significant gains, with companies like Vanke A and Longfor Group rising over 5% [1]. - China Evergrande's stock price is now fixed at 0.16 HKD, with a total market value of approximately 21.52 billion HKD [1][5]. Group 2: Delisting and Legal Proceedings - China Evergrande was delisted due to being suspended for over 18 months, with the Hong Kong Stock Exchange announcing the suspension of trading effective January 29, 2024 [3]. - The company faced a liquidity crisis starting in 2021, leading to a prolonged suspension of its shares and subsequent debt restructuring efforts [3][4]. Group 3: Financial Losses and Investigations - In July 2023, China Evergrande reported cumulative losses exceeding 800 billion RMB for the years 2021 and 2022, setting a record for the highest losses by a Chinese company [4]. - The China Securities Regulatory Commission has initiated an investigation into Evergrande's financial practices, including allegations of premature revenue recognition [4]. Group 4: Liquidation Process - The Hong Kong High Court has ordered the liquidation of China Evergrande, which is now the largest liquidation case among Hong Kong-listed companies [5]. - As of July 31, 2025, the liquidators have received 187 claims totaling approximately 350 billion HKD (about 45 billion USD), with ongoing asset liquidation efforts yielding around 20 billion HKD (2.55 billion USD) [5][6].

Core Viewpoint - The pharmaceutical market, particularly innovative drug companies, is experiencing significant growth, with substantial support from policies, leading to the emergence of high-performing stocks similar to Changchun Gaoxin. Group 1: Market Performance - The Hong Kong innovative drug index has increased from 859 points at the beginning of the year to 1284 points, representing a 50% rise [1] - The mainland innovative drug index has risen from a low of 948 to a high of 1156, showing a 22% increase, indicating a significant lag compared to Hong Kong [1] Group 2: Stock Performance - Several stocks in the Hong Kong innovative drug sector have seen substantial gains, such as: - Kintor Pharmaceutical rising from 2.48 to 19.78 HKD - Akeso increasing from 1.2 to 4.3 HKD - CanSino Biologics moving from 2 to 8.73 HKD - CStone Pharmaceuticals growing from 0.8 to 3.89 HKD - Innovent Biologics increasing from 26.45 to 105.5 HKD [4] - The current bullish trend in Hong Kong's innovative drug sector is viewed as just the beginning, with expectations of a long-term market cycle lasting 50 years [4] Group 3: Historical Comparisons - Historical data from 2005 to 2007 shows that Hong Kong real estate stocks typically initiated their upward trends over six months before A-share stocks, with A-share stocks generally experiencing greater increases [5] - Examples include: - China Overseas Land rising from 2.29 to 21.95 HKD - Vanke increasing from 6.76 to 33.82 HKD - Deep Zhenye rising from 19.90 to 271.8 HKD [5] - The patterns observed in the real estate sector may provide insights into the potential trajectory of mainland innovative drug stocks, suggesting a possible follow-up to the Hong Kong market's performance [5]